IOncology

Editor’s Note: As CDK4/6 inhibitors (CDK4/6i) secure their role in adjuvant therapy for HR+/HER2− early breast cancer, a central clinical challenge has emerged: how to maximize benefit while minimizing toxicity…

Editor’s Note: In recent years, systemic treatment options for HER2-positive breast cancer brain metastases have made meaningful progress, yet substantial unmet clinical needs remain. At the 2025 San Antonio Breast…

Editor's Note: HER2-positive breast cancer has a high incidence of brain metastases. In the era when treatment relied primarily on local therapies, patient survival outcomes were poor. The PERMEATE study…

At the recent ESMO-ASIA Congress, Professor Takayuki delivered an in-depth interpretation of the latest follow-up data from the Asian subgroup of the KEYNOTE-859 study. The presentation explored the long-term clinical value of pembrolizumab plus chemotherapy as a first-line treatment for Asian patients with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, providing a comprehensive look at the regimen's durable efficacy over a 5-year timeframe.

Editor’s Note: In a recent academic presentation, Prof. Do-Youn Oh (Seoul National University College of Medicine) shared updated long-term results from the Asian subgroup of the Phase III KEYNOTE-859 study,…

Editor’s Note: At a recent GI oncology symposium, Prof. Jung Yong Hong (Samsung Medical Center, South Korea) presented safety results from the Phase 3b SIERRA study, focusing on Asian patients…

Editor’s Note: In an oral presentation selected by the ESMO Asia Scientific Committee, Dr. David Tai (Singapore) presented updated subgroup analyses from the Phase III CheckMate 9DW study, examining the…

Editor’s Note: Despite the success of immune checkpoint inhibitors (ICIs) in GI tumors, immune resistance and the immunosuppressive tumor microenvironment (TME) remain major barriers. At a recent symposium, Prof. Kohei…

Editor’s note: From its early focus on “standards, safety and standardized practice” to today’s deep integration of clinical, basic, and translational research, the 8th Shanghai International Medical Oncology Symposium (SIMOS)…

At the recently concluded European Society for Medical Oncology Asia Congress (ESMO Asia), participating experts shared and reviewed the latest advances in numerous breast cancer clinical studies. Oncology Frontier has…